Purpose: To determine the contribution of the C282Y and H63D mutations in the HFE gene to clinical expression of hereditary hemochromatosis. Methods: Pooled analysis of 14 case-control studies reporting HFE genotype data, to evaluate the association of different HFEgenotypes with iron overload. In addition, we used data from the pooled analysis and published data to estimate the penetrance of the C282Y/C282Y genotype. Results: Hornozygosity for the C282Y mutation carried the largest risk for iron overload (OR = 4383, 95% C I 1374 to >10,000) and accounted forthe majority of hernochromatosis cases {attributable fraction (AF) = 0.73). Risks for other genotypes were much smaller: OR = 32 for genotype C282Y/H63D (95% CI 18.5 to 55.4, AF = 0.06); OR = 5.7 for H63D/N63D (95% CI 3.2 to 10.1, AF = 0.01); OR = 4.1 for C282Y heterozygcsity ((95% CI 2.9 to 5.8, with heterogeneity in study results, making this association uncertain); and OR = 1.6 for HGJD heterozygosity (95% CI 1 to 2.6, AF = 0.03). Estimates of penetrance for the C282Y/C282Y genotype were hrghly sens~tive to estimates of the prevalence of iron overload disease. At a prevalence of 2.5 per 1000 or less, penetrance of the C282Y/C282Y genotype is unlikely to exceed 50%. Penetrance of other HFE genotypes is much lower. Conclusions: C282Y homozygosity confers the highest risk for iron overload but the H63D mutation is also associated with increased risk. Key Words: hemochromatosis, iron overload, HFE gene. C2&2Y mutation, H63D mutation, penetrance
types and the clinical expression of hemochromatosis must be established.
In published clinical studies, the majority of hemochromatosis cases have been homozygous for the C282Y mutation, but the percentage in different populations has varied from 52 to 100%.3.7-21 Among the remaining cases, several other HFE genotypes have been found, including compound heterozygotes (C282Y/H63D, 0 -7% of cases), H63D homozygotes (0-4% of cases), and heterozygotes for each of the two known mutations (0-1 5% of cases). There were no identifiable HFE mutations in O to 21% of cases.
The low frequency of compound heterozygotes (C282YI H63D) and H63D homozygotes among hernachromatosis cases is unexpected, because the H63D mutation is more common than the C282Y mutations in the general population.
Among control subjects, H63D heterozygotes are consistently found two to three times more frequently than C282Y hete r o z y g o t e~.~~~~~~~~'~ As a result, genotypes containing the H63D mutation -including both the C282YIH63D and the H63DIH63D genotypes -occur more frequently in the population than the C282YIC282Y genotype. The low proportion of genotypes containing the H63D mutation among hemochromatosis cases thus suggests either a weak association with clinical expression of disease or lack of an association. The wits m Medicine association between the C282Y or H63D heterozygosity and clinical disease is also uncertain.
These observations make it difficult to determine what constitutes a positive result when HFE mutation testing is done. To address this question, we have performed a pooled analysis, using data from 14 studies that evaluated HFE genotypes in hemochrornatosis case and control populations. The purpose of the pooled analysis was to determine whether genotypes other than C282YlC282Y had a causal association with hemochromatosis or could be explained by chance. Data from the pooled analysis were also used, in combination with prevalence data, to estimate the penetrance of HFE genotypes.
Selection of studies for pooled analysis
The studies used in the pooled analysis were identified by a computerized search of the PubMed database (National Library of Medicine) done in September 1999, using the search terms "hemochrornatosis and HFE," and from the references cited in the articles located through the search. Studies were included if they met the following criteria: ( 1 ) the frequency of the HFE mutations C282Y and H63D was reported for persons with a diagnosis of hemochrornatosis and for control subjects; (2) the case definition for hemochrornatosis included a measure of iron overload (elevated serum ferritin, elevated hepatic iron index or other measure of excess iron based on liver biopsy, or evidence of iron overload by quantitative phlebotomy), with cases otherwise unselected; and (3) the population studied was Caucasian. When more than one study reported data from the same study population, we used the most recent published report. We identified 14 studies meeting these criteria.3.s-13,15-a1 These studies reported on study populations from Europe, New Zealand, and North America. In most studies, case and control subjects were recruited from different sources ( Table 1) . Most studies derived cases from clinical referral centers; however, three s t~d i e s~~,~~.~~ derived cases from a screened population. Case definitions for each study are summarized in Table 1 .
Statistical analysis
We computed the odds ratio (OR) for hemochrornatosis for each of five HFE genotypes that included a known mutation (C282Y/C282Y, C282Y/H63D, H63D/H63D, C282Y/+, H63D/+ ), using individuals with neither mutation as the referent group. ORs were computed both for the individual studies and for the pooled analysis of 14 studies, using the MantelHaenszel procedure.22 To rule out marked variation that would invalidate a pooled analysis, we assessed the heterogeneity of ORs across studies using the Breslow-Day test. Using the pooled OR, we estimated a crude population attributable fraction (AF, defined as the proportion of cases with disease attributable to a particular genotype) for the different genotypes in each study using Miettinen's formula as shown be-10~22; this estimate was not weighted by individual study size. 
Estimates of penetrance
We defined penetrance as the number of persons with a given genotype who manifest iron overload disease during their lifetime, divided by the total number of people with the genotype. Penetrance (P) was estimated using the following formula, where Pr,,, = the prevalence of iron overload disease due to hemochromatosis, C, , , , , = the proportion of cases of iron overload disease due to the C282YIC282Y genotype, and Pr,,,,, = the prevalence of the C282Y genotype:
Penetrance of C282YlC282Y = [(Pr,,,)(Ccy,cy)]/Pr,,,cY
Values for the calculation were estimated as follows.
Prevalence of iron overload disease
Published reports were used to estimate the prevalence of iron overload disease due to hemochromatosis.15~23-26 These reports indicate that there is considerable uncertainty about the prevalence of iron overload disease, due to differences in case definition. Screening studies have estimated prevalence based on the presence of biochemical measures of iron overload (such as persistently elevated transferrin saturation in combination with an elevated serum ferritin or an abnormal liver biopsy) in people who may be asymptomatic. In such studies, the prevalence of iron overload disease is estimated to range from 2 to 5 per 1000.15,23-26 However, symptomatic expression of iron overload disease may occur in as few as 50% of persons with biochemical evidence iron overload,'3." and serious complications of iron overload may occur in even fewer. 28 For this reason, we have calculated penetrance of the C282YlC282Y genotype for three base cases varying in prevalence of iron overload disease from 1 per 1000 to 5 per 1000.
Proportion of cases due to C282Y/C282Y
Using combined data from the 14 studies in the pooled analysis, we assumed that 75% of cases carried the C282YIC282Y genotype in the base case. For sensitivity analyses, the proportion was varied from 55% to 95%.
Prevalence of the C282Y/C282Y genotype
The prevalence of the C282YlC282Y genotype used for the base case was estimated at 0.5%, from combined data of the four studies in the pooled analysis that used unselected screened populations to measure the prevalence of different HFE genotype^^^^'^-^^.^^; this value was consistent with other published data of HFE genotype p r e v a l e n~e .~~ For sensitivity analyses, the prevalence was varied from 0.4% to 0.6%. Perretrance of C282Y/H63D and H63D/H63D The same formula and the same range for prevalence of iron overload disease were used in calculations of the penetrance of the C282YlH63D and H63DlH63D genotypes. Combined data from the 14 studies in the pooled analysis were used for the estimates of the proportion of cases carrying each of these genotypes (6% for C282YlH63D and 1% for H63DlH63D). The prevalence rates of the C282YlH63D genotype (2.2%) and the H63DlH63D genotype (2.5%) were estimated by combining data from the four studies in the pooled analysis that measured the prevalence of different HFE genotypes in unselected screened population^.^^^^^^^^^^^ These values were consistent with other published data of HFE genotype pre~alence.'~
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RESULTS
Pooled ORs for the different HFE genotypes are shown in Table 2 . Homozygosity for the C282Y mutation conferred the highest risk for iron overload (OR = 4383, 95% CI 1374 to > 10,000) and accounted for the majority of hemochromatosis cases in all studies ( Table 2 ). The pooled AF for this genotype was 0.73.
Other HFE genotypes were also associated with iron overload ( Table 2 ). The OR for compound heterozygosity was 32 (95% CI 18.5 to 55.4), and the pooled AF was 0.06. Homozygosity for the H63D mutation carried a smaller risk for iron overload (OR = 5.7,95% CI 3.2 to 10.1), with a pooled AF of 0.01. The OR for C282Y heterozygosity was 4.1 (95% CI 2.9 to 5.8), with a pooled AF of 0.03; however, heterogeneity in the OR associated with this genotype was observed across studies ( P = 0.02). H63D heterozygosity was also associated with an increased risk of iron overload; the pooled OR was 1.9 (95% CI 1.5 to 2.5), with a pooled AF of 0.03.
Two of the studies in the pooled analysis13, used blood donors as control subjects. Because blood donation could mask affected status, these studies could have biased the results through misassignment of controls. Similarly, a study done in an Italian population19 could have biased results because of the lower prevalence of the C282Y mutation in this population. 19 Therefore, we repeated the pooled analysis after omitting these three studies. The results were equivalent to the pooled analysis of all 14 studies (ORs of 4389 for C282Y/C282Y, 30.9 for C292Y/H63D, 5.7 for H63D/H63D, 3.7 for C282Y/+ and 1.9 for H63D/+, with confidence intervals similar to those shown in Table 2 ).
Estimates for the penetrance of the C282YlC282Y genotype are shown in Figure 1 and in Table 3 . Figure 1 shows changes in estimated penetrance with differences in the prevalence of iron overload and the proportion of cases carrying the C282Yl C282Y genotype. These calculations assume a genotype prevalence of 5 per 1000. Under these conditions, penetrance approaches 100% only when two conditions are present: (1) the prevalence of iron overload disease is 5 per 1000, and (2) the proportion of cases carrying the C282YIC282Y genotype also approaches 100%. As the proportion of cases with the C282Yl C282Y genotype decreases, so does penetrance. For lower rates of iron overload disease, penetrance is always below 50% and falls between 10% and 20% when iron overload is estimated at 1 in 1000. Table 3 shows the effect of differences in the prevalence of the genotype: as the prevalence of C282YlC282Y increases, penetrance decreases.
We also estimated the penetrance of the C282YlH63D and H63DIH63D genotypes (Table 4) . Estimates are shown for prevalence of symptomatic iron overload disease ranging from 1 per 1000 to 5 per 1000. The penetrance for these genotypes was very low: penetrance of the C282YlH63D genotype ranged from 0.3% to 1.4%, and penetrance of the H63DlH63D genotype ranged from 0.04°/~ to 0.2%.
DISCUSSION
Data from the pooled analysis confirm that the C282Yl C282Y genotype accounts for the majority of cases of iron overload due to hemochromatosis. However, in our analysis about 25% of cases had other HFE genotypes, including 14% with a normal HFE genotype. The pooled ORs indicate that both C282Y and H63D contribute to the clinical expression of hemochromatosis, although the penetrance of the C282Yl C282Y genotype is substantially higher than that of all other genotypes containing HFE mutations. These findings are consistent with studies of HFE protein function, which indicate a greater functional impairment with the C282Y mutation than with the H63D m~tation.3~-3' C282Y heterozygosity may be associated with increased risk, but heterogeneity in the OR estimates for this genotype across studies suggests the risk is influenced by additional factors. The Table 2 pooled epidemiologic analysis of 14 studies assessing the contribution of different HFE genotypes to the etiology of hereditaV hemochromatosis Table 3 C282YlC282Y penetrance: effect of differences in prevalence of genotype"
Prevalence of iron overload disease
Penetrance of due to Prevalence of C282YIC282Y hemochromatosis C282YIC282Y
"Calculations assume 75% of cases carry C282YlC282Y genotype.
Table 4
Penetrance of the C82YlH63D and H63DlH63D genotypes* Prevalence of iron overload disease Penetrance of Penetrance of due to C282YlH63D H63DIH63D hemochromatosis 0'0) ) "Calculations assume that C282YlH63D has a prevalence of 2.2% and occurs in 6% of cases and that H63DIH63D has a prevalence of 2.7% and occurs in 1 % of cases.
existence of additional mutations contributing to the development of hemochromatosis would be a plausible explanation for this finding. An additional mutation in the HFE gene, S65C, has been described recently, and may explain some cases of clinical expression in C282Y heterozygotes.I7 However, nongenetic factors might also modify the risk conferred by the heterozygous state.
Our estimate of the penetrance of the C282YlC282Y genotype varied with assumptions concerning the prevalence of iron overload disease, the prevalence of the genotype, and the proportion cases due to the genotype. Prevalence of iron overload disease had the greatest effect on penetrance estimates (Fig. 1, Table 3 ). Penetrance of the C282YIC282Y genotype exceeded 50% only when the prevalence of iron overload disease was set at 5 per 1000.
In fact, current data make it difficult to estimate the prevalence of iron overload disease with accuracy. Screening studies suggest that the prevalence of people with biochemical measures of iron overload may be as high as 5 per 1000.23 However, a substantial proportion of such people may be asymptomatic.23.27,2X One clinical study estimated that 43% of men and 28% of women with iron overload will develop serious complications of hemochromatosis2~ this study was based on the experience of patients seen in a referral center and may represent an upper estimate of p e n e t r a n~e .~~ No prospective studies have evaluated the likelihood of disease progression in persons found to have biochemical evidence of iron overload at a young age, but screening studies document persons with biochemical measures of iron overload who are asymptomatic at elderly Furthermore, case reports have documented elderly people with the C282YlC282Y genotype who have no clinical evidence of disease.36.37
Similarly, clinical diagnoses of hemochromatosis are much less common than would be expected from estimates of iron overload derived from screening studies." For example, death statistics and hospital records suggest a hemochromatosis prevalence of 1 to 3 per 10,000,-3X a figure that is 10-fold lower than estimates derived from screening studies. Missed diagnoses may contribute to this discrepancy but are unlikely to account fully for it. Clinical complications of hemochromatosis thus could fall at the lower end of our sensitivity analysis (i.e., at 1 per 1000), yielding a penetrance range for the C282YI C282Y genotype of 10% to 20%.
The penetrance of the C282YlH63D and H63DlH63D genotypes is much lower than the penetrance of the C282Yl C282Y genotype. Yet persons carrying these genotypes are still at substantially increased risk for iron overload disease, compared with persons with a normal HFE genotype. Thus, from a clinical perspective, our study indicates that there is no simple way to define a "positive" or "negative" genetic test for hemochromatosis based on HFE genotype. Even an imperfect genetic test may have clinical utility, but any use of HFE genotype tests for screening or diagnosis must take into account their uncertain predictive value for iron overload disease and, in particular, the limited sensitivity of tests using only the C282Y mutation.
These findings should be interpreted cautiously because of possible biases in the studies used for the pooled analysis. Sources of bias include the lack of uniformity of case definitions (e.g., studies used different diagnostic criteria, included incident and prevalent cases, and were likely to have included case subjects at different stages of the natural history of hemochromatosis), the possible inappropriateness of the control populations, and the lack of consideration of relevant modifiers such as gender, iron intake, and alcohol use. It is unlikely, however, that these biases can account for the large ORs obtained in the pooled analysis.
Another potential limitation in our results derives from reports of a polymorphism in the HFE gene that may cause an error in PCR analysis, resulting in the misclassification of C282Y heterozygotes as homozyg0tes.39.~~ If this error occurred in the studies included in the pooled analysis, it would cause our analysis to underestimate the penetrance of the C282YIC282Y genotype. However, investigation by the European Haemochromatosis Consortium and a proficiency testing program sponsored by the American College of Medical Genetics and the College of American Pathologists indicate that genotyping errors due to this polymorphism are likely to be rare.41,42
Well-designed population-based epidemiologic studies are needed to better characterize the impact of the different HFE genotypes on the absolute and relative risk of clinical complications due to iron overload and to define modifying factors that may contribute to the clinical expression of iron overload due to hemochromatosis. These research efforts will be aided by a consistent case definition for hernochromatosis and systematic measurement of known or potential modifiers of clinical expression such as gender, alcohol use, and hepatitis exposure.l,2 Knowledge about genotype-phenotype relationships in hemochromatosis will be improved by such efforts, but our data indicate that the HFE genotype will remain an imperfect predictor of clinical disease.
